[S02DA03, antipyrine, The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Acenocoumarol.]
[A14AA02, stanozolol, Stanozolol may increase the anticoagulant activities of Acenocoumarol.]
[G03XB02, ulipristal, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Ulipristal.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Acenocoumarol.]
[J01GA01, streptomycin, The risk or severity of bleeding can be increased when Streptomycin is combined with Acenocoumarol.]
[L01AD04, streptozocin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Streptozocin.]
[A02BX02, sucralfate, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Sucralfate.]
[J01CA16, sulbenicillin, Sulbenicillin may increase the anticoagulant activities of Acenocoumarol.]
[J01EC02, sulfadiazine, The metabolism of Acenocoumarol can be decreased when combined with Sulfadiazine.]
[J01ED07, sulfamerazine, The risk or severity of bleeding can be increased when Sulfamerazine is combined with Acenocoumarol.]
[S01AB01, sulfamethizole, The metabolism of Acenocoumarol can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The serum concentration of Acenocoumarol can be increased when it is combined with Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The risk or severity of bleeding can be increased when Sulfamethoxypyridazine is combined with Acenocoumarol.]
[J01EC03, sulfamoxole, The metabolism of Acenocoumarol can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Acenocoumarol can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Acenocoumarol can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Acenocoumarol can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Acenocoumarol.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Acenocoumarol.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Acenocoumarol.]
[M01AX04, apazone, The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Acenocoumarol.]
[L01BB02, mercaptopurine, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Mercaptopurine.]
[N06DA01, tacrine, The metabolism of Acenocoumarol can be decreased when combined with Tacrine.]
[J01CA15, talampicillin, Talampicillin may increase the anticoagulant activities of Acenocoumarol.]
[L02BA01, tamoxifen, The risk or severity of bleeding can be increased when Tamoxifen is combined with Acenocoumarol.]
[L01CB02, teniposide, The serum concentration of Acenocoumarol can be increased when it is combined with Teniposide.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may increase the anticoagulant activities of Acenocoumarol.]
[G03BA03, testosterone, The metabolism of Acenocoumarol can be increased when combined with Testosterone.]
[S03AA02, tetracycline, The serum concentration of Acenocoumarol can be increased when it is combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, The risk or severity of bleeding can be increased when Ceftaroline fosamil is combined with Acenocoumarol.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Acenocoumarol.]
[A04AD10, dronabinol, The metabolism of Acenocoumarol can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Acenocoumarol.]
[L04AX02, thalidomide, The risk or severity of bleeding can be increased when Thalidomide is combined with Acenocoumarol.]
[R03DA07, theobromine, The metabolism of Acenocoumarol can be decreased when combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Acenocoumarol can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Acenocoumarol can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Eribulin.]
[J01BA02, thiamphenicol, The risk or severity of bleeding can be increased when Thiamphenicol is combined with Acenocoumarol.]
[L01AC01, thiotepa, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Tioguanine.]
[N05CA19, thiopental, The serum concentration of Acenocoumarol can be increased when it is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Acenocoumarol.]
[N05AC02, thioridazine, The metabolism of Acenocoumarol can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be decreased when combined with Acenocoumarol.]
[J01CA13, ticarcillin, Ticarcillin may increase the anticoagulant activities of Acenocoumarol.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Acenocoumarol.]
[S01ED01, timolol, The metabolism of Acenocoumarol can be decreased when combined with Timolol.]
[P01AB02, tinidazole, The risk or severity of bleeding can be increased when Tinidazole is combined with Acenocoumarol.]
[S01AA12, tobramycin, The risk or severity of bleeding can be increased when Tobramycin is combined with Acenocoumarol.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Acenocoumarol.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Acenocoumarol.]
[M02AA21, tolmetin, The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Acenocoumarol.]
[N02AX02, tramadol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Tramadol.]
[N06AF04, tranylcypromine, The serum concentration of Acenocoumarol can be increased when it is combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Acenocoumarol.]
[N06AX05, trazodone, Trazodone may decrease the anticoagulant activities of Acenocoumarol.]
[L01XF01, tretinoin, The metabolism of Acenocoumarol can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, The metabolism of Acenocoumarol can be decreased when combined with Triamterene.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Trichlormethiazide.]
[N05AB06, trifluoperazine, The metabolism of Acenocoumarol can be decreased when combined with Trifluoperazine.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Acenocoumarol.]
[D07AC02, fluclorolone, Fluclorolone may increase the anticoagulant activities of Acenocoumarol.]
[R03BA07, mometasone, Mometasone may increase the anticoagulant activities of Acenocoumarol.]
[N03AC02, trimethadione, The metabolism of Acenocoumarol can be decreased when combined with Trimethadione.]
[J01EA01, trimethoprim, The metabolism of Acenocoumarol can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of bleeding can be increased when Trimipramine is combined with Acenocoumarol.]
[J01FA08, troleandomycin, The metabolism of Acenocoumarol can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Acenocoumarol.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Acenocoumarol.]
[R03DX07, roflumilast, The metabolism of Acenocoumarol can be decreased when combined with Roflumilast.]
[S01AA05, tyrothricin, The risk or severity of bleeding can be increased when Tyrothricin is combined with Acenocoumarol.]
[L02BX03, abiraterone, The serum concentration of Acenocoumarol can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Acenocoumarol can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Acenocoumarol can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Acenocoumarol can be decreased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Acenocoumarol can be increased when it is combined with Rilpivirine.]
[B01AD04, urokinase, Urokinase may increase the anticoagulant activities of Acenocoumarol.]
[A07AA12, fidaxomicin, The risk or severity of bleeding can be increased when Fidaxomicin is combined with Acenocoumarol.]
[S01AA28, vancomycin, The risk or severity of bleeding can be increased when Vancomycin is combined with Acenocoumarol.]
[B01AF01, rivaroxaban, Acenocoumarol may increase the anticoagulant activities of Rivaroxaban.]
[B01AC24, ticagrelor, The serum concentration of Acenocoumarol can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Acenocoumarol can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Acenocoumarol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Acenocoumarol can be increased when it is combined with Vinblastine.]
[L01CA03, vindesine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Vindesine.]
[A11HA03, vitamin E, Vitamin E may increase the anticoagulant activities of Acenocoumarol.]
[B01AA03, warfarin, The metabolism of Acenocoumarol can be increased when combined with Warfarin.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Acenocoumarol can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Acenocoumarol can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Acenocoumarol can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Acenocoumarol can be increased when it is combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Acenocoumarol can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin.]
[R03DC01, zafirlukast, The serum concentration of Acenocoumarol can be increased when it is combined with Zafirlukast.]
[A02BC04, rabeprazole, The serum concentration of Acenocoumarol can be increased when it is combined with Rabeprazole.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The serum concentration of Acenocoumarol can be increased when it is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Acenocoumarol.]
[L04AA34, alemtuzumab, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Alemtuzumab.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the anticoagulant activities of Acenocoumarol.]
[L01EJ01, ruxolitinib, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Ruxolitinib.]
[G04BD07, tolterodine, The metabolism of Acenocoumarol can be decreased when combined with Tolterodine.]
[J01DH04, doripenem, The risk or severity of bleeding can be increased when Doripenem is combined with Acenocoumarol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Acenocoumarol can be decreased when combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Rituximab.]
[J02AC03, voriconazole, Voriconazole may increase the anticoagulant activities of Acenocoumarol.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Acenocoumarol.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Acenocoumarol.]
[R07AX02, ivacaftor, The serum concentration of Acenocoumarol can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, Prednylidene may increase the anticoagulant activities of Acenocoumarol.]
[L01BC07, azacitidine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Azacitidine.]
[L04AX01, azathioprine, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Azathioprine.]
[L01BC05, gemcitabine, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Gemcitabine.]
[J01CA09, azlocillin, Azlocillin may increase the anticoagulant activities of Acenocoumarol.]
[J01DF01, aztreonam, The risk or severity of bleeding can be increased when Aztreonam is combined with Acenocoumarol.]
[R02AB04, bacitracin, The risk or severity of bleeding can be increased when Bacitracin is combined with Acenocoumarol.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Acenocoumarol.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Acenocoumarol.]
[L01XG02, carfilzomib, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Acenocoumarol can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Acenocoumarol can be decreased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Acenocoumarol can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Acenocoumarol can be increased when it is combined with Bosutinib.]
[L04AA31, teriflunomide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Acenocoumarol.]
[H02AA01, aldosterone, Aldosterone may increase the anticoagulant activities of Acenocoumarol.]
[L01EX05, regorafenib, The serum concentration of Acenocoumarol can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Acenocoumarol can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Acenocoumarol can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Acenocoumarol.]
[N04BD02, rasagiline, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Acenocoumarol.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Acenocoumarol.]
[N06DA02, donepezil, The metabolism of Acenocoumarol can be decreased when combined with Donepezil.]
[N03AX22, perampanel, The metabolism of Acenocoumarol can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Tofacitinib.]
[N02CC03, zolmitriptan, The metabolism of Acenocoumarol can be decreased when combined with Zolmitriptan.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Acenocoumarol.]
[H01CB05, pasireotide, The serum concentration of Acenocoumarol can be increased when it is combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hemorrhage can be increased when Acenocoumarol is combined with Sildenafil.]
[L01EA05, ponatinib, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Ponatinib.]
[B01AF02, apixaban, Apixaban may increase the anticoagulant activities of Acenocoumarol.]
[C10AX12, lomitapide, The serum concentration of Acenocoumarol can be increased when it is combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of bleeding can be increased when Bedaquiline is combined with Acenocoumarol.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Acenocoumarol can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Acenocoumarol.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Acenocoumarol.]
[N02BA10, benorilate, The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Acenocoumarol.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Acenocoumarol can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Acenocoumarol can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The risk or severity of bleeding can be increased when Tiratricol is combined with Acenocoumarol.]
[R02AD01, benzocaine, The metabolism of Acenocoumarol can be decreased when combined with Benzocaine.]
[J02AX04, caspofungin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Caspofungin.]
[M01AH01, celecoxib, The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Acenocoumarol.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Acenocoumarol.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The serum concentration of Acenocoumarol can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Acenocoumarol can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Acenocoumarol.]
[L01EE01, trametinib, The metabolism of Acenocoumarol can be increased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Acenocoumarol.]
[N06AX28, levomilnacipran, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Acenocoumarol.]
[A10BJ03, lixisenatide, Lixisenatide can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA03, cholic acid, The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Cholic Acid.]
[L01EL01, ibrutinib, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Acenocoumarol.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Acenocoumarol.]
[G03AC08, etonogestrel, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Etonogestrel.]
[N03AF04, eslicarbazepine, The metabolism of Acenocoumarol can be increased when combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Acenocoumarol can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The serum concentration of Acenocoumarol can be increased when it is combined with Simeprevir.]
[A10BK01, dapagliflozin, The metabolism of Acenocoumarol can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The metabolism of Acenocoumarol can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Acenocoumarol can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Acenocoumarol can be increased when combined with Apremilast.]
[P01CX04, miltefosine, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Miltefosine.]
[L02BG02, formestane, The metabolism of Acenocoumarol can be increased when combined with Formestane.]
[S03BA03, betamethasone, Betamethasone may increase the anticoagulant activities of Acenocoumarol.]
[S01ED02, betaxolol, The metabolism of Acenocoumarol can be decreased when combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Acenocoumarol.]
[C10AB02, bezafibrate, The risk or severity of bleeding can be increased when Bezafibrate is combined with Acenocoumarol.]
[L04AC11, siltuximab, The metabolism of Acenocoumarol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Acenocoumarol can be increased when it is combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Acenocoumarol.]
[J01XA04, dalbavancin, The risk or severity of bleeding can be increased when Dalbavancin is combined with Acenocoumarol.]
[S01AA13, fusidic acid, The serum concentration of Acenocoumarol can be increased when it is combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Pipemidic acid.]
[J01XX11, tedizolid, The risk or severity of bleeding can be increased when Tedizolid is combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Acenocoumarol can be increased when combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Acenocoumarol can be increased when it is combined with Idelalisib.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Acenocoumarol.]
[L03AB13, peginterferon beta-1a, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Acenocoumarol can be decreased when combined with Suvorexant.]
[J01XA05, oritavancin, The risk or severity of bleeding can be increased when Oritavancin is combined with Acenocoumarol.]
[S01AA15, dihydrostreptomycin, The risk or severity of bleeding can be increased when Dihydrostreptomycin is combined with Acenocoumarol.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Acenocoumarol.]
[L01BC08, decitabine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Decitabine.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Acenocoumarol.]
[L01EX09, nintedanib, The risk or severity of bleeding can be increased when Nintedanib is combined with Acenocoumarol.]
[S03AA06, gentamicin, The risk or severity of bleeding can be increased when Gentamicin is combined with Acenocoumarol.]
[L01FX07, blinatumomab, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Blinatumomab.]
[L01XK01, olaparib, The serum concentration of Acenocoumarol can be increased when it is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Acenocoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Acenocoumarol.]
[N06AX11, mirtazapine, Mirtazapine may increase the anticoagulant activities of Acenocoumarol.]
[L04AC10, secukinumab, The metabolism of Acenocoumarol can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Acenocoumarol can be increased when it is combined with Palbociclib.]
[N02BE01, acetaminophen, The serum concentration of Acenocoumarol can be increased when it is combined with Acetaminophen.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Acenocoumarol can be increased when combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Acenocoumarol.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Acenocoumarol.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Acenocoumarol.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Acenocoumarol.]
[M02AA25, aceclofenac, The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Acenocoumarol.]
[M01AB11, acemetacin, The risk or severity of bleeding and hemorrhage can be increased when Acenocoumarol is combined with Acemetacin.]
[S01EC01, acetazolamide, The serum concentration of Acenocoumarol can be increased when it is combined with Acetazolamide.]
[S02AA10, acetic acid, The risk or severity of bleeding can be increased when Acetic acid is combined with Acenocoumarol.]
[A02BC03, lansoprazole, The serum concentration of Acenocoumarol can be increased when it is combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Acenocoumarol.]
[J02AC05, isavuconazole, The serum concentration of Acenocoumarol can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Acenocoumarol can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The metabolism of Acenocoumarol can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Acenocoumarol can be decreased when combined with Cobimetinib.]
[V03AB35, sugammadex, The risk or severity of bleeding and hemorrhage can be increased when Acenocoumarol is combined with Sugammadex.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Acenocoumarol.]
[M04AB05, lesinurad, The metabolism of Acenocoumarol can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Acenocoumarol can be increased when it is combined with Elbasvir.]
[N05CA05, aprobarbital, The metabolism of Acenocoumarol can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Acenocoumarol.]
[N02BA02, aloxiprin, Aloxiprin may increase the anticoagulant activities of Acenocoumarol.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Acenocoumarol.]
[L01XX52, venetoclax, The serum concentration of Acenocoumarol can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Acenocoumarol.]
[N04BC01, bromocriptine, The serum concentration of Acenocoumarol can be increased when it is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Acenocoumarol.]
[N06AA19, amineptin, The risk or severity of bleeding can be increased when Amineptine is combined with Acenocoumarol.]
[D01AE16, amorolfine, Amorolfine may increase the anticoagulant activities of Acenocoumarol.]
[N05AX17, pimavanserin, The metabolism of Acenocoumarol can be decreased when combined with Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Acenocoumarol.]
[A05AA04, obeticholic acid, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Obeticholic acid.]
[N01BB01, bupivacaine, The metabolism of Acenocoumarol can be decreased when combined with Levobupivacaine.]
[N07BC01, buprenorphine, The serum concentration of Acenocoumarol can be increased when it is combined with Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Acenocoumarol.]
[L01AB01, busulfan, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Acenocoumarol can be increased when combined with Artemether.]
[M02AA03, clofezone, The serum concentration of Acenocoumarol can be increased when it is combined with Rabeprazole.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Sparfloxacin.]
[S01GX07, azelastine, The serum concentration of Acenocoumarol can be increased when it is combined with Azelastine.]
[J01CE04, azidocillin, Azidocillin may increase the anticoagulant activities of Acenocoumarol.]
[L01XK03, rucaparib, The metabolism of Acenocoumarol can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of adverse effects can be increased when Azithromycin is combined with Acenocoumarol.]
[J01CA06, bacampicillin, Bacampicillin may increase the anticoagulant activities of Acenocoumarol.]
[L01EF02, ribociclib, The metabolism of Acenocoumarol can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Acenocoumarol.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Acenocoumarol.]
[N06BC01, caffeine, The metabolism of Acenocoumarol can be decreased when combined with Caffeine.]
[D05AX03, calcitriol, The metabolism of Acenocoumarol can be increased when combined with Calcitriol.]
[J01XX08, linezolid, The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Acenocoumarol.]
[J05AE09, tipranavir, The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Acenocoumarol.]
[H03BA03, benzylthiouracil, Benzylthiouracil may increase the anticoagulant activities of Acenocoumarol.]
[L04AB02, infliximab, The metabolism of Acenocoumarol can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Acenocoumarol can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Acenocoumarol can be increased when combined with Brigatinib.]
[N04BD03, safinamide, The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Acenocoumarol.]
[L04AC14, sarilumab, The serum concentration of Acenocoumarol can be increased when it is combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Acenocoumarol can be increased when combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Betrixaban.]
[D01AC10, bifonazole, The serum concentration of Acenocoumarol can be increased when it is combined with Bifonazole.]
[L01BC06, capecitabine, Acenocoumarol may increase the anticoagulant activities of Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Acenocoumarol can be increased when it is combined with Enasidenib.]
[L01XH01, vorinostat, Vorinostat may increase the anticoagulant activities of Acenocoumarol.]
[J05AG03, efavirenz, The metabolism of Acenocoumarol can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of bleeding can be increased when Cefprozil is combined with Acenocoumarol.]
[L01BA03, raltitrexed, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Raltitrexed.]
[R03BA02, budesonide, Budesonide may increase the anticoagulant activities of Acenocoumarol.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Acenocoumarol.]
[M01AB07, bumadizone, The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Acenocoumarol.]
[L01EL02, acalabrutinib, The serum concentration of Acenocoumarol can be increased when it is combined with Acalabrutinib.]
[J05AX18, letermovir, The serum concentration of Acenocoumarol can be increased when it is combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of bleeding can be increased when Butriptyline is combined with Acenocoumarol.]
[B02BX06, emicizumab, The therapeutic efficacy of Emicizumab can be decreased when used in combination with Acenocoumarol.]
[N01BX04, capsaicin, The serum concentration of Acenocoumarol can be increased when it is combined with Capsaicin.]
[L02BB05, apalutamide, The serum concentration of Acenocoumarol can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Acenocoumarol can be increased when combined with Carbamazepine.]
[J01CA03, carbenicillin, Carbenicillin may increase the anticoagulant activities of Acenocoumarol.]
[H03BB01, carbimazole, Carbimazole may increase the anticoagulant activities of Acenocoumarol.]
[L03AB06, interferon alfa-n1, The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Acenocoumarol can be decreased when combined with Carvedilol.]
[B02BX09, fostamatinib, The serum concentration of Acenocoumarol can be increased when it is combined with Fostamatinib.]
[V03AB38, andexanet alfa, The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Acenocoumarol.]
[N03AX24, cannabidiol, The metabolism of Acenocoumarol can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Acenocoumarol can be increased when combined with Avatrombopag.]
[J01DE01, cefepime, The risk or severity of bleeding can be increased when Cefepime is combined with Acenocoumarol.]
[J01DD10, cefetamet, The risk or severity of bleeding can be increased when Cefetamet is combined with Acenocoumarol.]
[J01DD09, cefodizime, The risk or severity of bleeding can be increased when Cefodizime is combined with Acenocoumarol.]
[J01DC11, ceforanide, The risk or severity of bleeding can be increased when Ceforanide is combined with Acenocoumarol.]
[J01DD13, cefpodoxime, The risk or severity of bleeding can be increased when Cefpodoxime is combined with Acenocoumarol.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Acenocoumarol.]
[J01DD14, ceftibuten, The risk or severity of bleeding can be increased when Ceftibuten is combined with Acenocoumarol.]
[J01GB14, plazomicin, The risk or severity of bleeding can be increased when Plazomicin is combined with Acenocoumarol.]
[L01XX62, ivosidenib, The metabolism of Acenocoumarol can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Acenocoumarol can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Acenocoumarol can be increased when combined with Tecovirimat.]
[J01AA13, eravacycline, Eravacycline may increase the anticoagulant activities of Acenocoumarol.]
[L01EM04, duvelisib, The metabolism of Acenocoumarol can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Acenocoumarol can be decreased when combined with Dacomitinib.]
[J01AA14, sarecycline, Sarecycline may increase the anticoagulant activities of Acenocoumarol.]
[J01AA15, omadacycline, Omadacycline may increase the anticoagulant activities of Acenocoumarol.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Acenocoumarol.]
[M01AC05, lornoxicam, The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Acenocoumarol.]
[R03DA02, oxtriphylline, The metabolism of Acenocoumarol can be decreased when combined with Oxtriphylline.]
[M03BA02, carisoprodol, The metabolism of Acenocoumarol can be decreased when combined with Carisoprodol.]
[L01ED05, lorlatinib, The metabolism of Acenocoumarol can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Acenocoumarol can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Acenocoumarol can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The metabolism of Acenocoumarol can be decreased when combined with Gilteritinib.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Acenocoumarol.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Acenocoumarol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Acenocoumarol.]
[C10AB08, ciprofibrate, The risk or severity of bleeding can be increased when Ciprofibrate is combined with Acenocoumarol.]
[P02BX04, triclabendazole, The metabolism of Acenocoumarol can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Acenocoumarol can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Acenocoumarol can be decreased when combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Acenocoumarol can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Solriamfetol is combined with Acenocoumarol.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Acenocoumarol.]
[N05BA09, clobazam, The metabolism of Acenocoumarol can be increased when combined with Clobazam.]
[J01AA11, clomocycline, Clomocycline may increase the anticoagulant activities of Acenocoumarol.]
[H02AB14, cloprednol, Cloprednol may increase the anticoagulant activities of Acenocoumarol.]
[C01EB09, ubidecarenone, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Acenocoumarol can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Acenocoumarol can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, Cortivazol may increase the anticoagulant activities of Acenocoumarol.]
[L01EM03, alpelisib, The serum concentration of Acenocoumarol can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, The risk or severity of bleeding can be increased when Cefaclor is combined with Acenocoumarol.]
[J01DB05, cefadroxil, The risk or severity of bleeding can be increased when Cefadroxil is combined with Acenocoumarol.]
[J01DC03, cefamandole, The risk or severity of bleeding can be increased when Cefamandole is combined with Acenocoumarol.]
[J01DB07, cefatrizine, The risk or severity of bleeding can be increased when Cefatrizine is combined with Acenocoumarol.]
[J01DB04, cefazolin, The risk or severity of bleeding can be increased when Cefazolin is combined with Acenocoumarol.]
[J01CF03, methicillin, Meticillin may increase the anticoagulant activities of Acenocoumarol.]
[J01DC09, cefmetazole, The risk or severity of bleeding can be increased when Cefmetazole is combined with Acenocoumarol.]
[J01DC06, cefonicid, The risk or severity of bleeding can be increased when Cefonicid is combined with Acenocoumarol.]
[J01DD12, cefoperazone, The risk or severity of bleeding can be increased when Cefoperazone is combined with Acenocoumarol.]
[J01DD01, cefotaxime, The risk or severity of bleeding can be increased when Cefotaxime is combined with Acenocoumarol.]
[J01DC05, cefotetan, The risk or severity of bleeding can be increased when Cefotetan is combined with Acenocoumarol.]
[J01DC07, cefotiam, The risk or severity of bleeding can be increased when Cefotiam is combined with Acenocoumarol.]
[J01DC01, cefoxitin, The risk or severity of bleeding can be increased when Cefoxitin is combined with Acenocoumarol.]
[J01DD03, cefsulodin, The risk or severity of bleeding can be increased when Cefsulodin is combined with Acenocoumarol.]
[J01DD02, ceftazidime, The risk or severity of bleeding can be increased when Ceftazidime is combined with Acenocoumarol.]
[J01DD07, ceftizoxime, The risk or severity of bleeding can be increased when Ceftizoxime is combined with Acenocoumarol.]
[J01DD04, ceftriaxone, The risk or severity of bleeding can be increased when Ceftriaxone is combined with Acenocoumarol.]
[S01AA27, cefuroxime, The risk or severity of bleeding can be increased when Cefuroxime is combined with Acenocoumarol.]
[M03BX08, cyclobenzaprine, The metabolism of Acenocoumarol can be decreased when combined with Cyclobenzaprine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Acenocoumarol.]
[N07XX11, pitolisant, The serum concentration of Acenocoumarol can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Acenocoumarol can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Acenocoumarol can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Acenocoumarol.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Acenocoumarol.]
[A10AE03, insulin, regular, pork, The metabolism of Acenocoumarol can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The risk or severity of bleeding can be increased when Daptomycin is combined with Acenocoumarol.]
[J01DB01, cephalexin, The metabolism of Acenocoumarol can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of bleeding can be increased when Cefaloridine is combined with Acenocoumarol.]
[J01DB03, cephalothin, The risk or severity of bleeding can be increased when Cefalotin is combined with Acenocoumarol.]
[J01DB08, cephapirin, The risk or severity of bleeding can be increased when Cefapirin is combined with Acenocoumarol.]
[J01DB09, cephradine, The metabolism of Acenocoumarol can be increased when combined with Cefradine.]
[H02AB13, deflazacort, Deflazacort may increase the anticoagulant activities of Acenocoumarol.]
[G03DB05, demegestone, The risk or severity of adverse effects can be increased when Demegestone is combined with Acenocoumarol.]
[G03AC09, desogestrel, The risk or severity of adverse effects can be increased when Desogestrel is combined with Acenocoumarol.]
[B06AX03, voxelotor, The serum concentration of Acenocoumarol can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Acenocoumarol can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Acenocoumarol can be increased when it is combined with Givosiran.]
[L01EX18, avapritinib, The metabolism of Acenocoumarol can be decreased when combined with Avapritinib.]
[L01XX72, tazemetostat, The metabolism of Acenocoumarol can be decreased when combined with Tazemetostat.]
[M01AX21, diacetylrhein, The metabolism of Acenocoumarol can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The serum concentration of Acenocoumarol can be increased when it is combined with Remdesivir.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Acenocoumarol can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Acenocoumarol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Acenocoumarol can be decreased when combined with Frovatriptan.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Acenocoumarol.]
[G03DB08, dienogest, The risk or severity of adverse effects can be increased when Dienogest is combined with Acenocoumarol.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Acenocoumarol.]
[M01AH02, rofecoxib, The metabolism of Acenocoumarol can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Acenocoumarol can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The serum concentration of Acenocoumarol can be increased when it is combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Acenocoumarol can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The serum concentration of Acenocoumarol can be increased when it is combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The serum concentration of Acenocoumarol can be increased when it is combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Acenocoumarol.]
[L01EX17, capmatinib, The serum concentration of Acenocoumarol can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, Fluprednidene may increase the anticoagulant activities of Acenocoumarol.]
[M01AC04, droxicam, The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Acenocoumarol.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Acenocoumarol.]
[R06AX22, ebastine, The metabolism of Acenocoumarol can be decreased when combined with Ebastine.]
[P01BB01, proguanil, Proguanil may increase the anticoagulant activities of Acenocoumarol.]
[L04AC19, satralizumab, The serum concentration of Acenocoumarol can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The serum concentration of Acenocoumarol can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Chlorothiazide.]
[G03CA06, chlorotrianisene, Chlorotrianisene may decrease the anticoagulant activities of Acenocoumarol.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Acenocoumarol.]
[N05AA01, chlorpromazine, The metabolism of Acenocoumarol can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Acenocoumarol.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acenocoumarol.]
[M03BB03, chlorzoxazone, The metabolism of Acenocoumarol can be decreased when combined with Chlorzoxazone.]
[N02BA07, ethenzamide, The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Acenocoumarol.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, Choline salicylate may increase the anticoagulant activities of Acenocoumarol.]
[G03DC06, ethynodiol, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Etynodiol.]
[M01AB08, etodolac, The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Acenocoumarol.]
[M02AA06, etofenamate, The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Acenocoumarol.]
[C10AB09, etofibrate, The risk or severity of bleeding can be increased when Etofibrate is combined with Acenocoumarol.]
[B06AC06, berotralstat, The serum concentration of Acenocoumarol can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Acenocoumarol can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Fludarabine.]
[M01AX25, chondroitin sulfates, Chondroitin sulfate may increase the anticoagulant activities of Acenocoumarol.]
[P03AX07, abametapir, The serum concentration of Acenocoumarol can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Acenocoumarol can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, The metabolism of Acenocoumarol can be increased when combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Acenocoumarol can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Acenocoumarol.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Acenocoumarol.]
[J01DD08, cefixime, The risk or severity of bleeding can be increased when Cefixime is combined with Acenocoumarol.]
[J01DD15, cefdinir, The risk or severity of bleeding can be increased when Cefdinir is combined with Acenocoumarol.]
[J01MB07, flumequine, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, Flunisolide may increase the anticoagulant activities of Acenocoumarol.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may increase the anticoagulant activities of Acenocoumarol.]
[R03CC15, formoterol, The metabolism of Acenocoumarol can be decreased when combined with Formoterol.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The serum concentration of Acenocoumarol can be increased when it is combined with Cimetidine.]
[R02AB03, fusafungin, The risk or severity of bleeding can be increased when Fusafungine is combined with Acenocoumarol.]
[N07CA02, cinnarizine, The metabolism of Acenocoumarol can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Acenocoumarol can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Acenocoumarol can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The serum concentration of Acenocoumarol can be increased when it is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cisplatin.]
[N06AB04, citalopram, The serum concentration of Acenocoumarol can be increased when it is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Acenocoumarol can be decreased when combined with Somapacitan.]
[J02AX07, ibrexafungerp, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Ibrexafungerp.]
[P01CA03, fexinidazole, The serum concentration of Acenocoumarol can be increased when it is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Acenocoumarol can be decreased when it is combined with Belzutifan.]
[H01AC09, lonapegsomatropin, The metabolism of Acenocoumarol can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The serum concentration of Acenocoumarol can be decreased when it is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Acenocoumarol can be decreased when combined with Avacopan.]
[M01AG01, mefenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Acenocoumarol.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Acenocoumarol.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Acenocoumarol.]
[J01FF01, clindamycin, The serum concentration of Acenocoumarol can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Acenocoumarol can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Acenocoumarol can be increased when it is combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Acenocoumarol can be decreased when combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Acenocoumarol.]
[J04BA01, clofazimine, The serum concentration of Acenocoumarol can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Acenocoumarol.]
[C10AB01, clofibrate, The metabolism of Acenocoumarol can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Acenocoumarol can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The metabolism of Acenocoumarol can be decreased when combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Acenocoumarol can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of bleeding can be increased when Clomipramine is combined with Acenocoumarol.]
[S01EA04, clonidine, The metabolism of Acenocoumarol can be decreased when combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Acenocoumarol can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Acenocoumarol can be decreased when combined with Vonoprazan.]
[A04AA01, ondansetron, The metabolism of Acenocoumarol can be decreased when combined with Ondansetron.]
[G01AF02, clotrimazole, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Clotrimazole.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Acenocoumarol.]
[J01CF02, cloxacillin, Cloxacillin may increase the anticoagulant activities of Acenocoumarol.]
[J05AX31, lenacapavir, The metabolism of Acenocoumarol can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The serum concentration of Acenocoumarol can be increased when it is combined with Clozapine.]
[J01GB12, arbekacin, The risk or severity of bleeding can be increased when Arbekacin is combined with Acenocoumarol.]
[D01AE11, haloprogin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Haloprogin.]
[H01AC08, somatrogon, The metabolism of Acenocoumarol can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Acenocoumarol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Acenocoumarol.]
[J01CA18, hetacillin, Hetacillin may increase the anticoagulant activities of Acenocoumarol.]
[M04AC01, colchicine, The serum concentration of Acenocoumarol can be increased when it is combined with Colchicine.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XX04, spectinomycin, The risk or severity of bleeding can be increased when Spectinomycin is combined with Acenocoumarol.]
[J01XB01, colistin, The risk or severity of bleeding can be increased when Colistin is combined with Acenocoumarol.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, The risk or severity of bleeding can be increased when Cefpirome is combined with Acenocoumarol.]
[L04AA13, leflunomide, The serum concentration of Acenocoumarol can be decreased when it is combined with Leflunomide.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Acenocoumarol.]
[A10BX03, nateglinide, The metabolism of Acenocoumarol can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Acenocoumarol.]
[L01BB07, nelarabine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Acenocoumarol can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, Ciclesonide may increase the anticoagulant activities of Acenocoumarol.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Acenocoumarol.]
[M01AH03, valdecoxib, The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Acenocoumarol.]
[H01AX01, pegvisomant, The metabolism of Acenocoumarol can be increased when combined with Pegvisomant.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Acenocoumarol.]
[M01AH04, parecoxib, The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Acenocoumarol.]
[J02AC02, itraconazole, The metabolism of Acenocoumarol can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Acenocoumarol can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, The serum concentration of Acenocoumarol can be increased when it is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Acenocoumarol.]
[L01EA01, imatinib, Imatinib may increase the anticoagulant activities of Acenocoumarol.]
[J02AC04, posaconazole, The metabolism of Acenocoumarol can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Acenocoumarol can be decreased when combined with Esomeprazole.]
[S01BA03, cortisone, Cortisone may increase the anticoagulant activities of Acenocoumarol.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Acenocoumarol.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Acenocoumarol.]
[M02AA31, loxoprofen, The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Acenocoumarol.]
[J01DC08, loracarbef, The risk or severity of bleeding can be increased when Loracarbef is combined with Acenocoumarol.]
[C08CA11, manidipine, The serum concentration of Acenocoumarol can be increased when it is combined with Manidipine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Acenocoumarol.]
[H02AB15, meprednisone, Meprednisone may increase the anticoagulant activities of Acenocoumarol.]
[R06AD07, mequitazine, The serum concentration of Acenocoumarol can be increased when it is combined with Mequitazine.]
[J01DH02, meropenem, The risk or severity of bleeding can be increased when Meropenem is combined with Acenocoumarol.]
[J01CA14, methampicillin, Metampicillin may increase the anticoagulant activities of Acenocoumarol.]
[R06AE03, cyclizine, The metabolism of Acenocoumarol can be decreased when combined with Cyclizine.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Cyclopenthiazide.]
[J01FA03, midecamycin, The serum concentration of Acenocoumarol can be increased when it is combined with Midecamycin.]
[L01AA01, cyclophosphamide, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Acenocoumarol.]
[J04AB01, cycloserine, The risk or severity of bleeding can be increased when Cycloserine is combined with Acenocoumarol.]
[S01XA18, cyclosporine, The serum concentration of Acenocoumarol can be increased when it is combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Acenocoumarol can be decreased when combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Acenocoumarol can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Acenocoumarol.]
[C10AA07, rosuvastatin, The metabolism of Acenocoumarol can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Acenocoumarol.]
[M01AX22, morniflumate, The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Acenocoumarol.]
[C03XA02, conivaptan, The metabolism of Acenocoumarol can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cytarabine.]
[J05AF10, entecavir, The metabolism of Acenocoumarol can be decreased when combined with Entecavir.]
[M01AH05, etoricoxib, The serum concentration of Acenocoumarol can be increased when it is combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Acenocoumarol can be decreased when combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dactinomycin.]
[G03XA01, danazol, The metabolism of Acenocoumarol can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Acenocoumarol can be increased when combined with Dapsone.]
[L01DB02, daunorubicin, The serum concentration of Acenocoumarol can be increased when it is combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Acenocoumarol.]
[A04AD11, nabilone, The metabolism of Acenocoumarol can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Acenocoumarol.]
[B02BD03, anti-inhibitor coagulant complex, The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Acenocoumarol.]
[J01AA01, demeclocycline, Demeclocycline may increase the anticoagulant activities of Acenocoumarol.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Acenocoumarol.]
[N06AX06, nefazodone, The metabolism of Acenocoumarol can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Acenocoumarol can be decreased when combined with Nilutamide.]
[J01XX07, nitroxoline, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Nitroxoline.]
[G03DB04, nomegestrol, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Nomegestrol.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Acenocoumarol.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Acenocoumarol.]
[N06AB10, escitalopram, The risk or severity of bleeding can be increased when Escitalopram is combined with Acenocoumarol.]
[R02AA02, dequalinium, The risk or severity of bleeding can be increased when Dequalinium is combined with Acenocoumarol.]
[A07EC03, olsalazine, The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Acenocoumarol.]
[N06AA01, desipramine, The risk or severity of bleeding can be increased when Desipramine is combined with Acenocoumarol.]
[D07XC02, desoximetasone, Desoximetasone may increase the anticoagulant activities of Acenocoumarol.]
[H02AA03, desoxycorticosterone, Desoxycortone may increase the anticoagulant activities of Acenocoumarol.]
[J01DH03, ertapenem, The risk or severity of bleeding can be increased when Ertapenem is combined with Acenocoumarol.]
[J02AX05, micafungin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Micafungin.]
[L01XA03, oxaliplatin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Acenocoumarol.]
[N03AF02, oxcarbazepine, The serum concentration of Acenocoumarol can be increased when it is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, Dexamethasone may increase the anticoagulant activities of Acenocoumarol.]
[G04BD04, oxybutynin, The serum concentration of Acenocoumarol can be increased when it is combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Acenocoumarol can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Acenocoumarol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, Gefitinib may increase the anticoagulant activities of Acenocoumarol.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acenocoumarol.]
[N03AC01, paramethadione, The metabolism of Acenocoumarol can be decreased when combined with Paramethadione.]
[N06AB05, paroxetine, The serum concentration of Acenocoumarol can be increased when it is combined with Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Acenocoumarol.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Acenocoumarol.]
[A03AX15, peppermint oil, The serum concentration of Acenocoumarol can be increased when it is combined with Peppermint oil.]
[N05BA01, diazepam, The serum concentration of Acenocoumarol can be increased when it is combined with Diazepam.]
[J01CE05, phenethicillin, Pheneticillin may increase the anticoagulant activities of Acenocoumarol.]
[N06AA08, dibenzepin, The risk or severity of bleeding can be increased when Dibenzepin is combined with Acenocoumarol.]
[S01BC03, diclofenac, The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Acenocoumarol.]
[J01CF01, dicloxacillin, The metabolism of Acenocoumarol can be increased when combined with Dicloxacillin.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Acenocoumarol.]
[L01DC04, ixabepilone, The serum concentration of Acenocoumarol can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The serum concentration of Acenocoumarol can be increased when it is combined with Erlotinib.]
[L02AA01, diethylstilbestrol, The serum concentration of Acenocoumarol can be increased when it is combined with Diethylstilbestrol.]
[C08CA03, isradipine, The serum concentration of Acenocoumarol can be increased when it is combined with Isradipine.]
[D07XC04, diflucortolone, Difluocortolone may increase the anticoagulant activities of Acenocoumarol.]
[N02BA11, diflunisal, The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Acenocoumarol.]
[C02DB01, dihydralazine, The metabolism of Acenocoumarol can be decreased when combined with Dihydralazine.]
[J02AX06, anidulafungin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Anidulafungin.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may decrease the anticoagulant activities of Acenocoumarol.]
[C04AE04, dihydroergocristine, The metabolism of Acenocoumarol can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The serum concentration of Acenocoumarol can be increased when it is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The metabolism of Acenocoumarol can be decreased when combined with Hydromorphone.]
[L04AX04, lenalidomide, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lenalidomide.]
[J05AE08, atazanavir, The metabolism of Acenocoumarol can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of bleeding can be increased when Treprostinil is combined with Acenocoumarol.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the anticoagulant activities of Acenocoumarol.]
[C08DB01, diltiazem, The serum concentration of Acenocoumarol can be increased when it is combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The serum concentration of Acenocoumarol can be increased when it is combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Acenocoumarol.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Acenocoumarol.]
[J01CE03, propicillin, Propicillin may increase the anticoagulant activities of Acenocoumarol.]
[N02BB04, propyphenazone, The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Acenocoumarol.]
[M01AB14, proglumetacin, The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Acenocoumarol.]
[C05CA03, diosmin, The metabolism of Acenocoumarol can be decreased when combined with Diosmin.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Acenocoumarol.]
[R06AA02, diphenhydramine, The metabolism of Acenocoumarol can be decreased when combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Acenocoumarol.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Acenocoumarol.]
[N06BA11, dexmethylphenidate, The serum concentration of the active metabolites of Acenocoumarol can be increased when Acenocoumarol is used in combination with Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Acenocoumarol.]
[N06AA23, quinupramine, The risk or severity of bleeding can be increased when Quinupramine is combined with Acenocoumarol.]
[A03FA02, cisapride, The metabolism of Acenocoumarol can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Sirolimus.]
[C01BA03, disopyramide, The metabolism of Acenocoumarol can be decreased when combined with Disopyramide.]
[P03AA04, disulfiram, Disulfiram may increase the anticoagulant activities of Acenocoumarol.]
[S02AA12, rifamycin SV, The serum concentration of Acenocoumarol can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Acenocoumarol can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The metabolism of Acenocoumarol can be increased when combined with Rifaximin.]
[N07XX02, riluzole, The metabolism of Acenocoumarol can be decreased when combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Acenocoumarol.]
[N01BB09, ropivacaine, The metabolism of Acenocoumarol can be decreased when combined with Ropivacaine.]
[J01MB01, rosoxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The serum concentration of Acenocoumarol can be increased when it is combined with Sunitinib.]
[A04AD12, aprepitant, The serum concentration of Acenocoumarol can be increased when it is combined with Aprepitant.]
[L01XG01, bortezomib, The metabolism of Acenocoumarol can be decreased when combined with Bortezomib.]
[J05AE07, fosamprenavir, The serum concentration of Acenocoumarol can be increased when it is combined with Fosamprenavir.]
[S01BC05, ketorolac, The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Acenocoumarol.]
[C01EB18, ranolazine, The serum concentration of Acenocoumarol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Acenocoumarol.]
[A03FA03, domperidone, The metabolism of Acenocoumarol can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of bleeding can be increased when Dosulepin is combined with Acenocoumarol.]
[N06AA12, doxepin, The risk or severity of bleeding can be increased when Doxepin is combined with Acenocoumarol.]
[L01DB01, doxorubicin, The serum concentration of Acenocoumarol can be increased when it is combined with Doxorubicin.]
[J01AA02, doxycycline, The risk or severity of bleeding can be increased when Doxycycline is combined with Acenocoumarol.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Sertraline is combined with Acenocoumarol.]
[A08AA10, sibutramine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Acenocoumarol.]
[C10AA01, simvastatin, Simvastatin may increase the anticoagulant activities of Acenocoumarol.]
[G03DB01, dydrogesterone, Dydrogesterone may decrease the anticoagulant activities of Acenocoumarol.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Acenocoumarol.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Acenocoumarol.]
[H01AA01, corticotropin, Corticotropin may increase the anticoagulant activities of Acenocoumarol.]
[J01CG02, tazobactam, The risk or severity of bleeding can be increased when Tazobactam is combined with Acenocoumarol.]
[J01MA05, temafloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Temafloxacin.]
[J01CA17, temocillin, Temocillin may increase the anticoagulant activities of Acenocoumarol.]
[L01AX03, temozolomide, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Acenocoumarol.]
[D01BA02, terbinafine, The metabolism of Acenocoumarol can be increased when combined with Terbinafine.]
[A08AB01, orlistat, Orlistat may increase the anticoagulant activities of Acenocoumarol.]
[N06AX14, tianeptine, The risk or severity of bleeding can be increased when Tianeptine is combined with Acenocoumarol.]
[G03CX01, tibolone, Tibolone may increase the anticoagulant activities of Acenocoumarol.]
[G01AF08, tioconazole, The serum concentration of Acenocoumarol can be increased when it is combined with Tioconazole.]
[N05BA23, tofisopam, The serum concentration of Acenocoumarol can be increased when it is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Acenocoumarol.]
[N06AG03, toloxatone, The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Acenocoumarol.]
[N03AX11, topiramate, The metabolism of Acenocoumarol can be increased when combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of bleeding can be increased when Toremifene is combined with Acenocoumarol.]
[C03CA04, torsemide, The metabolism of Acenocoumarol can be decreased when combined with Torasemide.]
[J01AA12, tigecycline, The serum concentration of Acenocoumarol can be increased when it is combined with Tigecycline.]
[N05CC01, chloral hydrate, The protein binding of Acenocoumarol can be decreased when combined with Chloral hydrate.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Acenocoumarol.]
[H02CA01, trilostane, Trilostane may increase the anticoagulant activities of Acenocoumarol.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Troxerutin.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Acenocoumarol.]
[J01MA04, enoxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Enoxacin.]
[L01CA04, vinorelbine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Vinorelbine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Acenocoumarol.]
[N06AX16, venlafaxine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Venlafaxine.]
[C08CA12, mepirodipine, The serum concentration of Acenocoumarol can be increased when it is combined with Barnidipine.]
[S01EA01, epinephrine, The serum concentration of Acenocoumarol can be increased when it is combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Epirubicin.]
[N05CF02, zolpidem, The metabolism of Acenocoumarol can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Acenocoumarol.]
[N03AX15, zonisamide, The metabolism of Acenocoumarol can be decreased when combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Acenocoumarol can be decreased when combined with Zopiclone.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Acenocoumarol.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Acenocoumarol.]
[L01XA02, carboplatin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Acenocoumarol.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Acenocoumarol.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acenocoumarol.]
[N02CA02, ergotamine, The metabolism of Acenocoumarol can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The risk or severity of bleeding can be increased when Erythromycin is combined with Acenocoumarol.]
[A02BC02, pantoprazole, The metabolism of Acenocoumarol can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Acenocoumarol can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The risk or severity of adverse effects can be increased when Estradiol is combined with Acenocoumarol.]
[G03CC06, estriol, Estriol may decrease the anticoagulant activities of Acenocoumarol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Acenocoumarol can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Acenocoumarol can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, Fluticasone furoate may increase the anticoagulant activities of Acenocoumarol.]
[R03BA05, fluticasone, Fluticasone may increase the anticoagulant activities of Acenocoumarol.]
[C10AA04, fluvastatin, The metabolism of Acenocoumarol can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Acenocoumarol.]
[J04AD03, ethionamide, The risk or severity of bleeding can be increased when Ethionamide is combined with Acenocoumarol.]
[N03AB01, ethotoin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Ethotoin.]
[M01AC06, meloxicam, The risk or severity of bleeding can be increased when Meloxicam is combined with Acenocoumarol.]
[L01CB01, etoposide, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Etoposide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Acenocoumarol.]
[L04AD02, tacrolimus, The serum concentration of Acenocoumarol can be increased when it is combined with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The serum concentration of Acenocoumarol can be increased when it is combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Acenocoumarol can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Acenocoumarol.]
[N06AB08, fluvoxamine, The serum concentration of Acenocoumarol can be increased when it is combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Acenocoumarol can be decreased when combined with Tocainide.]
[R01AX06, mupirocin, The risk or severity of bleeding can be increased when Mupirocin is combined with Acenocoumarol.]
[C10AA03, pravastatin, The risk or severity of bleeding can be increased when Pravastatin is combined with Acenocoumarol.]
[B02BD08, factor VIIa, The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Acenocoumarol.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Acenocoumarol.]
[A05AA01, chenodeoxycholic acid, The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Deoxycholic acid.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dextran.]
[B02BD07, factor XIII, The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Acenocoumarol.]
[V03AF02, dexrazoxane, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dexrazoxane.]
[A02BA03, famotidine, The metabolism of Acenocoumarol can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Levocarnitine.]
[P02CA03, albendazole, The metabolism of Acenocoumarol can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Acenocoumarol can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The metabolism of Acenocoumarol can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Acenocoumarol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Acenocoumarol.]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Acenocoumarol.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cladribine.]
[C01BC04, flecainide, The metabolism of Acenocoumarol can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Acenocoumarol.]
[J01CF05, floxacillin, The metabolism of Acenocoumarol can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Acenocoumarol can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Flucytosine.]
[H02AA02, fludrocortisone, Fludrocortisone may increase the anticoagulant activities of Acenocoumarol.]
[D07XB01, flumethasone, Flumethasone may increase the anticoagulant activities of Acenocoumarol.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Acenocoumarol.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Acenocoumarol.]
[D07AC08, fluocinonide, Fluocinonide may increase the anticoagulant activities of Acenocoumarol.]
[N06AA14, melitracen, The risk or severity of bleeding can be increased when Melitracen is combined with Acenocoumarol.]
[H02AB03, fluocortolone, Fluocortolone may increase the anticoagulant activities of Acenocoumarol.]
[V03AZ01, ethanol, The serum concentration of Acenocoumarol can be increased when it is combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Acenocoumarol can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, Fluorometholone may increase the anticoagulant activities of Acenocoumarol.]
[L01BC02, fluorouracil, The metabolism of Acenocoumarol can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Acenocoumarol.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the anticoagulant activities of Acenocoumarol.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Acenocoumarol.]
[S01BC04, flurbiprofen, The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Acenocoumarol.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Acenocoumarol.]
[L02BB01, flutamide, The metabolism of Acenocoumarol can be decreased when combined with Flutamide.]
[S02AA17, fosfomycin, The risk or severity of bleeding can be increased when Fosfomycin is combined with Acenocoumarol.]
[S01AA07, framycetin, The risk or severity of bleeding can be increased when Framycetin is combined with Acenocoumarol.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Acenocoumarol.]
[G01AX06, furazolidone, The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Acenocoumarol.]
[J05AE10, darunavir, The serum concentration of Acenocoumarol can be increased when it is combined with Darunavir.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Acenocoumarol.]
[N03AA04, barbexaclone, The metabolism of Acenocoumarol can be increased when combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Acenocoumarol.]
[C10AB04, gemfibrozil, The metabolism of Acenocoumarol can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of bleeding can be increased when Telavancin is combined with Acenocoumarol.]
[L01EA02, dasatinib, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Acenocoumarol.]
[N04BC06, cabergoline, The serum concentration of Acenocoumarol can be increased when it is combined with Cabergoline.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Acenocoumarol.]
[J05AG04, etravirine, The metabolism of Acenocoumarol can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The metabolism of Acenocoumarol can be decreased when combined with Methsuximide.]
[G03XA02, gestrinone, The risk or severity of adverse effects can be increased when Gestrinone is combined with Acenocoumarol.]
[L02AB03, gestronol, Gestonorone may decrease the anticoagulant activities of Acenocoumarol.]
[L01EH01, lapatinib, The serum concentration of Acenocoumarol can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The serum concentration of Acenocoumarol can be increased when it is combined with Glyburide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Acenocoumarol.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Acenocoumarol.]
[H04AA01, glucagon, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Glucagon.]
[M01AX05, glucosamine, Glucosamine may increase the anticoagulant activities of Acenocoumarol.]
[N05CM18, dexmedetomidine, The metabolism of Acenocoumarol can be decreased when combined with Dexmedetomidine.]
[N05CE01, glutethimide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Glutethimide.]
[C02CA04, doxazosin, The metabolism of Acenocoumarol can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Acenocoumarol.]
[L01EX02, sorafenib, Sorafenib may increase the anticoagulant activities of Acenocoumarol.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Fluindione.]
[R02AB30, gramicidin, The risk or severity of bleeding can be increased when Gramicidin D is combined with Acenocoumarol.]
[D01BA01, griseofulvin, The metabolism of Acenocoumarol can be increased when combined with Griseofulvin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Acenocoumarol.]
[N01AB01, halothane, The metabolism of Acenocoumarol can be decreased when combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Acenocoumarol.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Acenocoumarol.]
[L01CE02, irinotecan, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Irinotecan.]
[B06AB01, hemin, Hemin may increase the anticoagulant activities of Acenocoumarol.]
[M04AA01, allopurinol, The risk or severity of bleeding can be increased when Allopurinol is combined with Acenocoumarol.]
[C09CA01, losartan, The serum concentration of Acenocoumarol can be increased when it is combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Acenocoumarol.]
[G03DC01, allylestrenol, The metabolism of Acenocoumarol can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Acenocoumarol.]
[L01XX03, altretamine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Altretamine.]
[G01AX16, hexetidine, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Hexetidine.]
[N05CA16, hexobarbital, The metabolism of Acenocoumarol can be increased when combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Acenocoumarol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The serum concentration of Acenocoumarol can be increased when it is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Acenocoumarol.]
[C02DB02, hydralazine, The serum concentration of Acenocoumarol can be increased when it is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, Hydrocortisone may increase the anticoagulant activities of Acenocoumarol.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Hydroflumethiazide.]
[G03DA03, 17-alpha-hydroxyprogesterone, Hydroxyprogesterone may decrease the anticoagulant activities of Acenocoumarol.]
[L01XX05, hydroxyurea, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Hydroxyurea.]
[J04AB04, rifabutin, The metabolism of Acenocoumarol can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Acenocoumarol can be decreased when combined with Ibuprofen.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of bleeding can be increased when Ifosfamide is combined with Acenocoumarol.]
[H01AC02, somatrem, The metabolism of Acenocoumarol can be increased when combined with Somatrem.]
[N06AA02, imipramine, The risk or severity of bleeding can be increased when Imipramine is combined with Acenocoumarol.]
[L01CD01, paclitaxel, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Paclitaxel.]
[J01XA02, teicoplanin, The risk or severity of bleeding can be increased when Teicoplanin is combined with Acenocoumarol.]
[R01AD07, tixocortol, Tixocortol may increase the anticoagulant activities of Acenocoumarol.]
[M03BX02, tizanidine, The metabolism of Acenocoumarol can be decreased when combined with Tizanidine.]
[L01CE01, topotecan, The serum concentration of Acenocoumarol can be increased when it is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Acenocoumarol.]
[L03AB04, interferon alfa-2a, The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The serum concentration of Acenocoumarol can be increased when it is combined with Milnacipran.]
[D03BA02, collagenase, The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Collagenase clostridium histolyticum.]
[N05CH02, ramelteon, The metabolism of Acenocoumarol can be decreased when combined with Ramelteon.]
[C10AA06, cerivastatin, The serum concentration of Acenocoumarol can be increased when it is combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Acenocoumarol.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Acenocoumarol.]
[L03AB09, interferon alfacon-1, The metabolism of Acenocoumarol can be decreased when combined with Interferon alfacon-1.]
[N06AA13, iprindole, The risk or severity of bleeding can be increased when Iprindole is combined with Acenocoumarol.]
[N06AF05, iproniazid, The metabolism of Acenocoumarol can be decreased when combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Acenocoumarol can be decreased when combined with Penciclovir.]
[N06AF01, isocarboxazid, The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Acenocoumarol.]
[P01AX06, atovaquone, The metabolism of Acenocoumarol can be decreased when combined with Atovaquone.]
[J04AC01, isoniazid, The serum concentration of Acenocoumarol can be increased when it is combined with Isoniazid.]
[A10BJ01, exenatide, Exenatide can cause an increase in the absorption of Acenocoumarol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[P02CF01, ivermectin, Ivermectin may increase the anticoagulant activities of Acenocoumarol.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Acenocoumarol.]
[J01FA07, josamycin, The serum concentration of Acenocoumarol can be increased when it is combined with Josamycin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Acenocoumarol.]
[C04AF01, kininogenase, The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Acenocoumarol.]
[S01AA24, kanamycin, The risk or severity of bleeding can be increased when Kanamycin is combined with Acenocoumarol.]
[H01AC01, somatropin, The metabolism of Acenocoumarol can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Acenocoumarol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Acenocoumarol can be increased when combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Acenocoumarol.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Acenocoumarol.]
[J02AB02, ketoconazole, The metabolism of Acenocoumarol can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Acenocoumarol can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Acenocoumarol can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Acenocoumarol.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding can be increased when Acenocoumarol is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Acenocoumarol can be increased when combined with Abatacept.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Rotigotine is combined with Acenocoumarol.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Acenocoumarol.]
[C07AG01, labetalol, The metabolism of Acenocoumarol can be decreased when combined with Labetalol.]
[A06AD11, lactulose, The risk or severity of bleeding can be increased when Lactulose is combined with Acenocoumarol.]
[N03AX18, lacosamide, The metabolism of Acenocoumarol can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, The protein binding of Acenocoumarol can be decreased when combined with Etacrynic acid.]
[J01CA11, amdinocillin, Amdinocillin may increase the anticoagulant activities of Acenocoumarol.]
[J01CA08, amdinocillin pivoxil, Pivmecillinam may increase the anticoagulant activities of Acenocoumarol.]
[L01DC03, mitomycin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Mitomycin.]
[G03AD01, levonorgestrel, The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Acenocoumarol.]
[S02DA01, lidocaine, The metabolism of Acenocoumarol can be decreased when combined with Lidocaine.]
[J01FF02, lincomycin, The risk or severity of bleeding can be increased when Lincomycin is combined with Acenocoumarol.]
[S01AA21, amikacin, The risk or severity of bleeding can be increased when Amikacin is combined with Acenocoumarol.]
[N06BA13, armodafinil, The metabolism of Acenocoumarol can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Acenocoumarol.]
[N06AA07, lofepramine, The risk or severity of bleeding can be increased when Lofepramine is combined with Acenocoumarol.]
[L01AD02, lomustine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lomustine.]
[C10AA02, lovastatin, The serum concentration of Acenocoumarol can be increased when it is combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Acenocoumarol.]
[J01AA04, lymecycline, Lymecycline may increase the anticoagulant activities of Acenocoumarol.]
[G03DC03, lynestrenol, The risk or severity of adverse effects can be increased when Lynestrenol is combined with Acenocoumarol.]
[L01EG01, temsirolimus, The serum concentration of Acenocoumarol can be increased when it is combined with Temsirolimus.]
[L01EA03, nilotinib, The metabolism of Acenocoumarol can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The metabolism of Acenocoumarol can be decreased when combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Acenocoumarol.]
[L01AA05, mechlorethamine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Acenocoumarol.]
[G03DB03, medrogestone, Medrogestone may decrease the anticoagulant activities of Acenocoumarol.]
[P01BC02, mefloquine, The serum concentration of Acenocoumarol can be increased when it is combined with Mefloquine.]
[J01FG01, pristinamycin, The risk or severity of bleeding can be increased when Pristinamycin is combined with Acenocoumarol.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Acenocoumarol.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dalteparin.]
[N05CH01, melatonin, The metabolism of Acenocoumarol can be decreased when combined with Melatonin.]
[L01AA03, melphalan, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Melphalan.]
[N06DX01, memantine, The metabolism of Acenocoumarol can be decreased when combined with Memantine.]
[N02AB02, meperidine, The metabolism of Acenocoumarol can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Acenocoumarol can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Acenocoumarol can be increased when combined with Methylphenobarbital.]
[L02BG01, aminoglutethimide, The metabolism of Acenocoumarol can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Acenocoumarol.]
[G03BB01, mesterolone, Mesterolone may increase the anticoagulant activities of Acenocoumarol.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Acenocoumarol.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Acenocoumarol.]
[H01CB03, lanreotide, The serum concentration of Acenocoumarol can be increased when it is combined with Lanreotide.]
[J01AA05, methacycline, Metacycline may increase the anticoagulant activities of Acenocoumarol.]
[N07BC02, methadone, The serum concentration of Acenocoumarol can be increased when it is combined with Methadone.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Acenocoumarol.]
[J01XX05, methenamine, The risk or severity of bleeding can be increased when Methenamine is combined with Acenocoumarol.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Acenocoumarol.]
[H03BB02, methimazole, Methimazole may decrease the anticoagulant activities of Acenocoumarol.]
[L01BA04, pemetrexed, The metabolism of Acenocoumarol can be decreased when combined with Pemetrexed.]
[N05CA15, methohexital, The metabolism of Acenocoumarol can be increased when combined with Methohexital.]
[L04AX03, methotrexate, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Acenocoumarol.]
[D05BA02, methoxsalen, The metabolism of Acenocoumarol can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Acenocoumarol can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The serum concentration of Acenocoumarol can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The serum concentration of Acenocoumarol can be increased when it is combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Acenocoumarol can be decreased when combined with Aminophylline.]
[N06BA04, methylphenidate, The metabolism of Acenocoumarol can be decreased when combined with Methylphenidate.]
[H02AB04, methylprednisolone, Methylprednisolone may increase the anticoagulant activities of Acenocoumarol.]
[D07AC14, methylprednisolone aceponate, Methylprednisolone aceponate may increase the anticoagulant activities of Acenocoumarol.]
[N03AF03, rufinamide, The metabolism of Acenocoumarol can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the anticoagulant activities of Acenocoumarol.]
[N02CA04, methysergide, The metabolism of Acenocoumarol can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The metabolism of Acenocoumarol can be decreased when combined with Metoclopramide.]
[P01AB01, metronidazole, The serum concentration of Acenocoumarol can be increased when it is combined with Metronidazole.]
[V04CD01, metyrapone, The serum concentration of Acenocoumarol can be increased when it is combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Acenocoumarol can be decreased when combined with Mexiletine.]
[J01CA10, mezlocillin, Mezlocillin may increase the anticoagulant activities of Acenocoumarol.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Acenocoumarol.]
[S02AA13, miconazole, The metabolism of Acenocoumarol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Acenocoumarol.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Acenocoumarol can be increased when it is combined with Midazolam.]
[G03XB01, mifepristone, The serum concentration of Acenocoumarol can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Tinzaparin.]
[C09CA03, valsartan, The metabolism of Acenocoumarol can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the anticoagulant activities of Acenocoumarol.]
[J01FA11, miocamycin, The metabolism of Acenocoumarol can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Acenocoumarol can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Mitoxantrone.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Acenocoumarol.]
[L03AC01, aldesleukin, The serum concentration of Acenocoumarol can be increased when it is combined with Aldesleukin.]
[C01BD01, amiodarone, The risk or severity of bleeding can be increased when Amiodarone is combined with Acenocoumarol.]
[N06AA09, amitriptyline, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Amitriptyline.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Acenocoumarol.]
[J01DD06, moxalactam, The risk or severity of bleeding can be increased when Latamoxef is combined with Acenocoumarol.]
[L04AB05, certolizumab pegol, The metabolism of Acenocoumarol can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Acenocoumarol.]
[L01EX03, pazopanib, The serum concentration of Acenocoumarol can be increased when it is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of bleeding can be increased when Mycophenolic acid is combined with Acenocoumarol.]
[N05CA02, amobarbital, The metabolism of Acenocoumarol can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Acenocoumarol can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The serum concentration of Acenocoumarol can be increased when it is combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of bleeding can be increased when Amoxapine is combined with Acenocoumarol.]
[N03AB05, fosphenytoin, The metabolism of Acenocoumarol can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1b.]
[J01CA04, amoxicillin, Amoxicillin may increase the anticoagulant activities of Acenocoumarol.]
[J01CF06, nafcillin, The metabolism of Acenocoumarol can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Acenocoumarol.]
[V03AB15, naloxone, The metabolism of Acenocoumarol can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Acenocoumarol can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the anticoagulant activities of Acenocoumarol.]
[M02AA12, naproxen, The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Acenocoumarol.]
[A10BG01, troglitazone, The metabolism of Acenocoumarol can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Acenocoumarol.]
[L01CD02, docetaxel, The serum concentration of Acenocoumarol can be increased when it is combined with Docetaxel.]
[L02BG04, letrozole, The metabolism of Acenocoumarol can be decreased when combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of bleeding can be increased when Neomycin is combined with Acenocoumarol.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Acenocoumarol.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Acenocoumarol.]
[J02AA01, amphotericin B, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may increase the anticoagulant activities of Acenocoumarol.]
[S01AA23, netilmicin, The risk or severity of bleeding can be increased when Netilmicin is combined with Acenocoumarol.]
[N06AX23, desvenlafaxine, The serum concentration of Acenocoumarol can be increased when it is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Acenocoumarol can be decreased when combined with Telmisartan.]
[L01XX01, amsacrine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Amsacrine.]
[C10AD02, niacin, The metabolism of Acenocoumarol can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Acenocoumarol.]
[C08CA04, nicardipine, The serum concentration of Acenocoumarol can be increased when it is combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Acenocoumarol can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Acenocoumarol can be increased when combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Acenocoumarol.]
[G01AX05, nifuratel, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Nifuratel.]
[R07AX01, nitric oxide, The serum concentration of Acenocoumarol can be increased when it is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The risk or severity of bleeding can be increased when Nitrofurantoin is combined with Acenocoumarol.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Acenocoumarol.]
[G03DC02, norethindrone, The risk or severity of adverse effects can be increased when Norethisterone is combined with Acenocoumarol.]
[S01AE02, norfloxacin, The serum concentration of Acenocoumarol can be increased when it is combined with Norfloxacin.]
[G03AC07, norgestrienone, The risk or severity of adverse effects can be increased when Norgestrienone is combined with Acenocoumarol.]
[C02KX01, bosentan, The metabolism of Acenocoumarol can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The risk or severity of bleeding can be increased when Nortriptyline is combined with Acenocoumarol.]
[R05DA07, noscapine, The serum concentration of Acenocoumarol can be increased when it is combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Acenocoumarol.]
[L03AB07, interferon beta-1a, The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of Acenocoumarol can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Ofloxacin.]
[J01FA05, oleandomycin, The serum concentration of Acenocoumarol can be increased when it is combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Acenocoumarol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The serum concentration of Acenocoumarol can be increased when it is combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of bleeding can be increased when Opipramol is combined with Acenocoumarol.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Acenocoumarol.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Ancrod.]
[J01CF04, oxacillin, Oxacillin may increase the anticoagulant activities of Acenocoumarol.]
[A14AA08, oxandrolone, The metabolism of Acenocoumarol can be decreased when combined with Oxandrolone.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Oxolinic acid.]
[A14AA05, oxymetholone, The serum concentration of Acenocoumarol can be increased when it is combined with Oxymetholone.]
[S01BC02, oxyphenbutazone, The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Acenocoumarol.]
[S01AA04, oxytetracycline, Oxytetracycline may increase the anticoagulant activities of Acenocoumarol.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the anticoagulant activities of Acenocoumarol.]
[N05AH05, asenapine, The metabolism of Asenapine can be decreased when combined with Acenocoumarol.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Danaparoid.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Tapentadol is combined with Acenocoumarol.]
[J04AB30, capreomycin, The risk or severity of bleeding can be increased when Capreomycin is combined with Acenocoumarol.]
[G03DB06, chlormadinone, The risk or severity of adverse effects can be increased when Chlormadinone is combined with Acenocoumarol.]
[H02AB05, paramethasone, Paramethasone may increase the anticoagulant activities of Acenocoumarol.]
[C02KC01, pargyline, The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Acenocoumarol.]
[A07AA06, paromomycin, The risk or severity of bleeding can be increased when Paromomycin is combined with Acenocoumarol.]
[J01MA03, pefloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Pefloxacin.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Acenocoumarol.]
[M01CC01, penicillamine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Penicillamine.]
[S01AA14, penicillin G, Benzylpenicillin may increase the anticoagulant activities of Acenocoumarol.]
[J01CE09, penicillin G procaine, Procaine benzylpenicillin may increase the anticoagulant activities of Acenocoumarol.]
[J01CE02, penicillin V, Phenoxymethylpenicillin may increase the anticoagulant activities of Acenocoumarol.]
[N05CA01, pentobarbital, The metabolism of Acenocoumarol can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Pentostatin.]
[C04AD03, pentoxifylline, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Pentoxifylline.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Acenocoumarol.]
[N05AB03, perphenazine, The metabolism of Acenocoumarol can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Acenocoumarol.]
[N06AF03, phenelzine, The serum concentration of Acenocoumarol can be increased when it is combined with Phenelzine.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Acenocoumarol.]
[N03AA02, phenobarbital, The metabolism of Acenocoumarol can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Acenocoumarol.]
[M02AA01, phenylbutazone, The metabolism of Acenocoumarol can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Acenocoumarol can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Acenocoumarol can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The metabolism of Acenocoumarol can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Acenocoumarol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Levofloxacin.]
[L02BB03, bicalutamide, The serum concentration of Acenocoumarol can be increased when it is combined with Bicalutamide.]
[B02BA01, vitamin K1, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Phylloquinone.]
[C08CX01, mibefradil, The serum concentration of Acenocoumarol can be increased when it is combined with Mibefradil.]
[S01EB01, pilocarpine, The serum concentration of Acenocoumarol can be increased when it is combined with Pilocarpine.]
[N05AG02, pimozide, The serum concentration of Acenocoumarol can be increased when it is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Acenocoumarol.]
[C10AA05, atorvastatin, The risk or severity of bleeding can be increased when Atorvastatin is combined with Acenocoumarol.]
[J01CA12, piperacillin, Piperacillin may increase the anticoagulant activities of Acenocoumarol.]
[J05AE01, saquinavir, The metabolism of Acenocoumarol can be decreased when combined with Saquinavir.]
[S01BC06, piroxicam, The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Acenocoumarol.]
[J01DD16, cefditoren, The risk or severity of bleeding can be increased when Cefditoren is combined with Acenocoumarol.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Grepafloxacin.]
[J01CA02, pivampicillin, Pivampicillin may increase the anticoagulant activities of Acenocoumarol.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Acenocoumarol.]
[J05AG02, delavirdine, The metabolism of Acenocoumarol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The serum concentration of Acenocoumarol can be increased when it is combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Acenocoumarol.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Acenocoumarol.]
[A10BG02, rosiglitazone, The metabolism of Acenocoumarol can be decreased when combined with Rosiglitazone.]
[A03AE01, alosetron, The metabolism of Acenocoumarol can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Acenocoumarol can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of bleeding can be increased when Polymyxin B is combined with Acenocoumarol.]
[C03AA05, polythiazide, The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Acenocoumarol can be decreased when it is combined with Ritonavir.]
[V03AB21, potassium iodide, Potassium Iodide may increase the anticoagulant activities of Acenocoumarol.]
[C10AA08, pitavastatin, The risk or severity of bleeding can be increased when Pitavastatin is combined with Acenocoumarol.]
[P02BA01, praziquantel, The metabolism of Acenocoumarol can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, Prednisolone may increase the anticoagulant activities of Acenocoumarol.]
[H02AB07, prednisone, Prednisone may increase the anticoagulant activities of Acenocoumarol.]
[P01BA03, primaquine, The serum concentration of Acenocoumarol can be increased when it is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Acenocoumarol can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Acenocoumarol can be increased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Acenocoumarol.]
[L01XB01, procarbazine, The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Acenocoumarol.]
[C10AB05, fenofibrate, The metabolism of Acenocoumarol can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, The metabolism of Acenocoumarol can be increased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Acenocoumarol can be decreased when combined with Promazine.]
[G03DB07, promegestone, Promegestone may decrease the anticoagulant activities of Acenocoumarol.]
[R06AD02, promethazine, The metabolism of Acenocoumarol can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Acenocoumarol can be decreased when combined with Propafenone.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Acenocoumarol.]
[L01XH02, romidepsin, Romidepsin may increase the anticoagulant activities of Acenocoumarol.]
[N01AX10, propofol, The serum concentration of Acenocoumarol can be increased when it is combined with Propofol.]
[N02AC04, propoxyphene, The serum concentration of Acenocoumarol can be increased when it is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Acenocoumarol can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the anticoagulant activities of Acenocoumarol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Acenocoumarol.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Acenocoumarol.]
[R03DC03, montelukast, The metabolism of Acenocoumarol can be decreased when combined with Montelukast.]
[J04AD01, prothionamide, The risk or severity of bleeding can be increased when Protionamide is combined with Acenocoumarol.]
[N06AA11, protriptyline, The risk or severity of bleeding can be increased when Protriptyline is combined with Acenocoumarol.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Acenocoumarol.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Acenocoumarol.]
[M09AB02, collagenase Clostridium histolyticum, The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Collagenase clostridium histolyticum.]
[J04AK01, pyrazinamide, The risk or severity of bleeding can be increased when Pyrazinamide is combined with Acenocoumarol.]
[C01BA01, quinidine, The serum concentration of Acenocoumarol can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Acenocoumarol can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Acenocoumarol can be increased when it is combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Acenocoumarol.]
[J04AB02, rifampin, The metabolism of Acenocoumarol can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Acenocoumarol.]
[J01AA09, rolitetracycline, Rolitetracycline may increase the anticoagulant activities of Acenocoumarol.]
[J01FA06, roxithromycin, The serum concentration of Acenocoumarol can be increased when it is combined with Roxithromycin.]
[C05CA01, rutin, The serum concentration of Acenocoumarol can be increased when it is combined with Rutin.]
[N02BA05, salicylamide, The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Acenocoumarol.]
[A07EC01, sulfasalazine, The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Acenocoumarol.]
[S01BC08, salicylic acid, The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Acenocoumarol.]
[N05CA06, secobarbital, The metabolism of Acenocoumarol can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Acenocoumarol.]
[L01FA03, obinutuzumab, The risk or severity of bleeding and hemorrhage can be increased when Acenocoumarol is combined with Obinutuzumab.]
[J01GB08, sisomicin, The risk or severity of bleeding can be increased when Sisomicin is combined with Acenocoumarol.]
[H01CB01, somatostatin, The serum concentration of Acenocoumarol can be increased when it is combined with Somatostatin.]
[L01CD04, cabazitaxel, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cabazitaxel.]
[J01FA02, spiramycin, The risk or severity of bleeding can be increased when Spiramycin is combined with Acenocoumarol.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Trastuzumab emtansine.]
[N03AG01, valproic acid, The serum concentration of Acenocoumarol can be increased when it is combined with Valproic acid.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), The therapeutic efficacy of Catridecacog can be decreased when used in combination with Acenocoumarol.]
[D07AB02, hydrocortisone butyrate, Hydrocortisone butyrate may increase the anticoagulant activities of Acenocoumarol.]
[A05AA02, ursodiol, The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Ursodeoxycholic acid.]
